Lv4
490 积分 2025-08-21 加入
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)
3小时前
已完结
A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates
2个月前
已关闭
Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours
2个月前
已完结
PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans
3个月前
已完结
Property-Based Prediction Uncovers Intestinal Excretion as an Elimination Route of Small-Molecule Drugs
6个月前
已完结
Use of pharmacokinetic versus pharmacodynamic endpoints to support human dose predictions: implications for rational drug design and early clinical development
8个月前
已完结
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy
8个月前
已完结
皖公网安备34019202002308
